Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 7

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population

Authors Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA

Received 14 August 2012

Accepted for publication 27 September 2012

Published 1 November 2012 Volume 2012:7 Pages 757—764

DOI https://doi.org/10.2147/COPD.S36997

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Margaret K Pasquale,1 Shawn X Sun,2 Frank Song,1 Heather J Hartnett,1 Stephen A Stemkowski1

1Competitive Health Analytics, Louisville, KY, USA; 2Health Economics and Outcomes Research, Forest Research Institute, Jersey City, NJ, USA

Background: Exacerbations of chronic obstructive pulmonary disease (COPD) lead to significant increases in resource utilization and cost to the health care system. COPD patients with chronic bronchitis and a history of exacerbations pose an additional burden to the system. This study examined health care utilization and cost among these patients.
Methods: For this retrospective analysis, data were extracted from a large national health plan with a predominantly Medicare population. This study involved patients who were aged 40–89 years, had been enrolled continuously for 24 months or more, had at least two separate insurance claims for COPD with chronic bronchitis (International Classification of Diseases, Ninth Revision, Clinical Modification code 491.xx), and had pharmacy claims for COPD maintenance medications between January 1, 2007, and March 31, 2009. Two years of data were examined for each patient; the index date was defined as the first occurrence of COPD. Baseline characteristics were obtained from the first year of data, with health outcomes tracked in the second year. Severe exacerbation was defined by COPD-related hospitalization or death; moderate exacerbation was defined by oral or parenteral corticosteroid use. Adjusted numbers of exacerbations and COPD-related costs per patient were estimated controlling for demographic and clinical characteristics.
Results: The final study sample involved 8554 patients; mean age was 70.1 ± 8.6 years and 49.8% of the overall population had exacerbation, 13.9% had a severe exacerbation only, 29.1% had a moderate exacerbation only, and 6.8% had both a severe and moderate exacerbation. COPD-related mean annual costs were $4069 (all figures given in US dollars) for the overall population and $6381 for patients with two or more exacerbations. All-cause health care costs were $18,976 for the overall population and $23,901 for patients with history of two or more exacerbations. Severity of exacerbations, presence of cardiovascular disease, diabetes, and long-term oxygen use were associated with higher adjusted costs.
Conclusions: The results indicate that despite treatment with maintenance medications, COPD patients continue to have exacerbations resulting in higher costs. New medications and disease management interventions are warranted to reduce the severity and frequency of exacerbations and the related cost impact of the disease.

Keywords: COPD with chronic bronchitis, moderate exacerbation, severe exacerbation, Medicare patients

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members

Pasquale MK, Xu Y, Baker CL, Zou KH, Teeter JG, Renda AM, Davis CC, Lee TC, Bobula J

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:111-121

Published Date: 14 January 2016

Readers of this article also read:

COPD exacerbation frequency and its association with health care resource utilization and costs

Dhamane AD, Moretz C, Zhou Y, Burslem K, Saverno K, Jain G, Renda A, Kaila S

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2609-2618

Published Date: 3 December 2015

Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer

Su H, Luo Q, Xie H, Huang XF, Ni YH, Mou YB, Hu QG

International Journal of Nanomedicine 2015, 10:1921-1930

Published Date: 10 March 2015

Microwave-assisted polyol synthesis of carbon nitride dots from folic acid for cell imaging

Guan WW, Gu W, Ye L, Guo CY, Su S, Xu PX, Xue M

International Journal of Nanomedicine 2014, 9:5071-5078

Published Date: 31 October 2014

Modulation of hydrogen sulfide by vascular hypoxia

Osmond JM, Kanagy NL

Hypoxia 2014, 2:117-126

Published Date: 25 August 2014

Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD

Moraes MR, da Costa AC, Corrêa KS, Junqueira-Kipnis AP, Rabahi MF

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:735-743

Published Date: 29 July 2014

Clinical issues of mucus accumulation in COPD

Ramos FL, Krahnke JS, Kim V

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:139-150

Published Date: 24 January 2014